TORONTO, June 24 /CNW/ - The Canadian Diabetes Association applauds the
Government of Ontario for increasing access to insulin detemir for Ontarians
living with diabetes. Insulin detemir, also known as Levemir has been added to
the Ontario Drug Formulary, effective June 23.
"The addition of insulin detemir to Ontario's drug formulary is an
important step in providing an option for those living with diabetes for whom
other insulin treatments have not been effective in controlling blood glucose
levels," said Gary O'Connor, Executive Director, Ontario, Canadian Diabetes
Association. "We appreciate the Government of Ontario for being committed to
the area of diabetes management and providing additional coverage for those
living with diabetes."
Insulin is a hormone produced by the pancreas to control the amount of
glucose (sugar) in the blood. For those living with diabetes, the pancreas
does not produce any or enough insulin, or is unable to effectively use the
insulin it does produce. As a result, glucose builds up in the bloodstream,
potentially leading to serious health problems such as blindness, heart
disease, kidney problems, amputation, nerve damage and erectile dysfunction.
The Ontario Drug Benefit (ODB) program administered by the Ontario
Ministry of Health and Long-term Care provides coverage for a number of drug
products including nutrition products and diabetes testing agents. For more
information on the ODB program, visit www.health.gov.on.ca
The Canadian Diabetes Association works in communities across the country
to promote the health of Canadians and eliminate diabetes through our strong
nationwide network of volunteers, employees, healthcare professionals,
researchers, partners and supporters. In the struggle against this global
epidemic, our expertise is recognized around the world. To learn more, visit
diabetes.ca or call 1-800-BANTING (226-8464).
For further information:
For further information: Randi Garcha, Associate, Marketing &
Communications, Ontario, Canadian Diabetes Association, Tel: (416) 408-7207,